BR112016004297A2 - método para o tratamento de doença fibrótica - Google Patents

método para o tratamento de doença fibrótica

Info

Publication number
BR112016004297A2
BR112016004297A2 BR112016004297A BR112016004297A BR112016004297A2 BR 112016004297 A2 BR112016004297 A2 BR 112016004297A2 BR 112016004297 A BR112016004297 A BR 112016004297A BR 112016004297 A BR112016004297 A BR 112016004297A BR 112016004297 A2 BR112016004297 A2 BR 112016004297A2
Authority
BR
Brazil
Prior art keywords
fibrotic disease
inhibitor
treating fibrotic
prophylaxis
treatment
Prior art date
Application number
BR112016004297A
Other languages
English (en)
Other versions
BR112016004297B1 (pt
Inventor
Marshall Diane
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112016004297A2 publication Critical patent/BR112016004297A2/pt
Publication of BR112016004297B1 publication Critical patent/BR112016004297B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção no geral diz respeito aos métodos de tratar doença fibrótica e mais especificamente a um inibidor da atividade de csf1-r para o tratamento e/ou profilaxia de doença fibrótica, em que o inibidor compreende uma entidade química pequena (nce), um ácido nucléico ou um anticorpo ou fragmento funcionalmente ativo ou derivado do mesmo. a presente invenção diz respeito ainda ao uso de um inibidor da atividade de csf-1r, para a fabricação de um medicamento para o tratamento e ou profilaxia de doença fibrótica.
BR112016004297-2A 2013-08-30 2014-08-26 uso de um inibidor da atividade de csf-1r BR112016004297B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1315486.9 2013-08-30
GBGB1315486.9A GB201315486D0 (en) 2013-08-30 2013-08-30 Antibodies
PCT/EP2014/068047 WO2015028454A2 (en) 2013-08-30 2014-08-26 Method for the treatment of fibrotic disease

Publications (2)

Publication Number Publication Date
BR112016004297A2 true BR112016004297A2 (pt) 2017-10-17
BR112016004297B1 BR112016004297B1 (pt) 2020-11-17

Family

ID=49397072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004297-2A BR112016004297B1 (pt) 2013-08-30 2014-08-26 uso de um inibidor da atividade de csf-1r

Country Status (17)

Country Link
US (1) US20160200820A1 (pt)
EP (1) EP3039041B1 (pt)
JP (1) JP6618471B2 (pt)
KR (1) KR102346566B1 (pt)
CN (2) CN105612181A (pt)
AU (1) AU2014314303B2 (pt)
BR (1) BR112016004297B1 (pt)
CA (1) CA2920931C (pt)
CL (1) CL2016000436A1 (pt)
ES (1) ES2786260T3 (pt)
GB (1) GB201315486D0 (pt)
IL (1) IL244042B (pt)
MX (1) MX2016002179A (pt)
MY (1) MY181808A (pt)
RU (1) RU2016111619A (pt)
SG (1) SG11201601149TA (pt)
WO (1) WO2015028454A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
MA44611A (fr) * 2016-04-04 2019-02-13 Massachusetts Inst Technology Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
CN110575540B (zh) * 2018-06-07 2021-11-02 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
KR102356829B1 (ko) * 2019-01-30 2022-01-28 주식회사 에프엔씨티바이오텍 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
WO2020159243A1 (ko) 2019-01-30 2020-08-06 한양대학교 산학협력단 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
KR102179518B1 (ko) 2019-03-29 2020-11-17 주식회사 혜안 황산염 자극에 의한 고로슬래그 활성화 무기 결합재 제조방법
US11430112B2 (en) * 2019-05-24 2022-08-30 PharmaNest LLC Systems and methods for quantitative phenotyping of fibrosis
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
WO2023091479A1 (en) * 2021-11-17 2023-05-25 AmMax Bio, Inc. Detection and treatment of idiopathic pulmonary fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
JP2006500012A (ja) * 2002-07-31 2006-01-05 ヌクレオニクス インコーポレーティッド 二本鎖ｒｎａの構造および構築物、並びにその作製法および使用法
JP5651285B2 (ja) * 2005-02-15 2015-01-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
WO2009026303A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
WO2009075344A1 (ja) * 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US8492357B2 (en) * 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
RU2591195C2 (ru) * 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
SG11201401639QA (en) * 2011-10-21 2014-05-29 Transgene Sa Modulation of macrophage activation
WO2013119716A1 (en) * 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors

Also Published As

Publication number Publication date
SG11201601149TA (en) 2016-03-30
CA2920931A1 (en) 2015-03-05
RU2016111619A3 (pt) 2018-05-17
BR112016004297B1 (pt) 2020-11-17
RU2016111619A (ru) 2017-10-05
WO2015028454A3 (en) 2015-05-21
GB201315486D0 (en) 2013-10-16
AU2014314303A1 (en) 2016-03-17
JP2016529265A (ja) 2016-09-23
IL244042A0 (en) 2016-04-21
WO2015028454A2 (en) 2015-03-05
EP3039041A2 (en) 2016-07-06
CN116036267A (zh) 2023-05-02
US20160200820A1 (en) 2016-07-14
CA2920931C (en) 2022-09-06
AU2014314303B2 (en) 2019-11-21
CL2016000436A1 (es) 2016-11-18
KR20160045891A (ko) 2016-04-27
KR102346566B1 (ko) 2021-12-31
JP6618471B2 (ja) 2019-12-11
ES2786260T3 (es) 2020-10-09
IL244042B (en) 2020-07-30
MX2016002179A (es) 2016-06-06
EP3039041B1 (en) 2020-03-04
MY181808A (en) 2021-01-07
CN105612181A (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
BR112016004297A2 (pt) método para o tratamento de doença fibrótica
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
BR112017014684A2 (pt) métodos de tratamento de doenças inflamatórias
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA201791711A1 (ru) Антитела к транстиретину
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
CY1121436T1 (el) Δοσολογια για τους αναστολεις των kinασων janus (jak)
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112016023554A2 (pt) novos compostos macrocíclicos
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201892438A1 (ru) 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt
BR112017025263A2 (pt) método para o tratamento de doença neurológica
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EA202190162A2 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
BR112014018712A8 (pt) Derivados de morfolinila úteis como inibidores de mogat-2
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2014, OBSERVADAS AS CONDICOES LEGAIS.